^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
ScTIL210
i
Other names: ScTIL210, Super circulating tumor infiltrating lymphocytes
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Beijing Cancer Hospital, Chineo Medical Technology
Drug class:
Immunomodulator
Related drugs:
over1year
A Clinical Study to Observe the Safety and Efficacy of ScTIL210 in the Treatment of Malignant Solid Tumors (clinicaltrials.gov)
P1/2, N=58, Recruiting, Shanghai East Hospital | Trial completion date: Dec 2022 --> Dec 2024 | Trial primary completion date: Dec 2021 --> Dec 2023
Trial completion date • Trial primary completion date
|
PD-1 (Programmed cell death 1)
|
PD-1 positive
|
ScTIL210
almost2years
Phase Ib Clinical Study on the Safety, the Tolerability, the Pharmacokinetics and the Efficacy of ScTIL Injection (Gene Modified Tumor Infiltrating Lymphocytes) Alone and in Combination With B Lymphocyte Adjuvant in the Treatment of Digestive System Malignant Solid Tumors (clinicaltrials.gov)
P1, N=48, Not yet recruiting, Peking University
New P1 trial • Combination therapy
|
PD-1 (Programmed cell death 1)
|
PD-1 positive
|
ScTIL210
over3years
A Clinical Study to Observe the Safety and Efficacy of ScTIL210 in the Treatment of Malignant Solid Tumors (clinicaltrials.gov)
P1/2, N=58, Recruiting, Shanghai East Hospital | Not yet recruiting --> Recruiting
Clinical • Enrollment open
|
CD19 (CD19 Molecule) • PD-1 (Programmed cell death 1)
|
ScTIL210
4years
A Clinical Study to Observe the Safety and Efficacy of ScTIL210 in the Treatment of Malignant Solid Tumors (clinicaltrials.gov)
P1/2, N=58, Not yet recruiting, Shanghai East Hospital
Clinical • New P1/2 trial
|
CD19 (CD19 Molecule) • PD-1 (Programmed cell death 1)
|
ScTIL210
Share via
